ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Interest Expense

Cost of servicing the company's debt during the period.

ProQR Therapeutics N.V.NASDAQ: PRQR

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was €0, compared with €0 a year earlier. Trailing-twelve-month interest expense was €0. Over 3 fiscal years it compounded at -44.7% a year.

Context

  • Interest expense amounted to 5.7% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near €0 or moves back toward the trailing-twelve-month quarterly average of €0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€0— QoQ
Last fiscal yearDec 2025
€866.4K-19.6% YoY
LTMMar 2026
€0-100.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-19.6%——
3-year CAGR-44.7%——
5-year CAGR——
10-year CAGR——

Interest Expense history

EUR · from the income statement

Latest · FY2025
866.4K EUR
Year-over-year change
-19.6%
4-year CAGR
-29.0%

Interest Expense vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the 5th highest of 6, against a peer median of -41.5%.
  • Interest expense amounts to 0.0% of revenue for PRQR, versus a peer median of 0.2%.
PRQR Competitors
Interest Expense for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$3.05M USD———
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$1.23M USD+270.1%——
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$908K USD-41.5%-22.9%—
MREOMereo BioPharma Group plcLTM Mar 2026$94.83K USD-92.3%-57.7%19.0%
IMMPImmutep LimitedFY2025A$24.01K AUD-21.5%-36.2%0.5%
PRQRProQR Therapeutics N.V.LTM Mar 2026€0 EUR-100.0%-44.7%0.0%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$0 USD——0.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 USD——0.0%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
ZURAZura Bio LimitedLTM Mar 2026$0 USD———
EDITEditas Medicine, Inc.LTM Mar 2026-$1.14M USD-151.6%—3.0%
Peer median (excluding PRQR) —-41.5%-36.2%0.2%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.